Literature DB >> 9498251

[Profile of ambulatory radiosurgery with the gamma knife system. 1: Method and multicenter irradiation concept].

B Wowra, H Czempiel, R Cibis, G A Horstmann.   

Abstract

Radiosurgery represents a minimally invasive radiologic method for the treatment of intracranial tumours and arteriovenous malformations. In 1994 the radiosurgical device 'Leksell Gamma Knife' (LGK) was installed in a dedicated logistic environment for outpatient treatments. High quality requirements have to be met for radiosurgery. The target point accuracy taking into account the whole system was shown to be reliably below 0.5 mm whereas the spatial therapeutic resolution was 0.035 cm3. Quality parameters of the dose plan were evaluated for the first 500 consecutive treatments. These values and examples of dose plans were used to emphasize the advantages of the treatment principle with multiple isocenters. An analysis of data in the literature revealed that there is no uniform standard of treatment available in radiosurgery. A highly significant correlation between a risk prediction model for the stereotactic linear accelerator on the one hand and a different model for the LGK on the other could be shown. This result could be helpful in order to proceed towards a more uniform treatment standard in radiosurgery and to improve overall treatment results.

Entities:  

Mesh:

Year:  1997        PMID: 9498251     DOI: 10.1007/s001170050313

Source DB:  PubMed          Journal:  Radiologe        ISSN: 0033-832X            Impact factor:   0.635


  2 in total

Review 1.  Treatment of brain metastases in renal cell carcinoma: radiotherapy, radiosurgery, or surgery?

Authors:  Alexander Muacevic; Michael Siebels; Jörg-Christian Tonn; Berndt Wowra
Journal:  World J Urol       Date:  2005-03-25       Impact factor: 4.226

Review 2.  Current concepts in stereotactic radiosurgery - a neurosurgical and radiooncological point of view.

Authors:  Jan Vesper; B Bölke; C Wille; P A Gerber; C Matuschek; M Peiper; H J Steiger; W Budach; G Lammering
Journal:  Eur J Med Res       Date:  2009-03-17       Impact factor: 2.175

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.